Interestingly, a recent preclinical study has reported that combining decitabine treatment with CD70 blockade significantly reduced AML LSC frequencies both in vitro and in vivo, with HSCs only marginally affected.37 This evidence concerns the gene CD70 and acute myeloid leukemia.